Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 889

1.

Aberrantly expressed PLOD1 promotes cancer aggressiveness in bladder cancer: a potential prognostic marker and therapeutic target.

Yamada Y, Kato M, Arai T, Sanada H, Uchida A, Misono S, Sakamoto S, Komiya A, Ichikawa T, Seki N.

Mol Oncol. 2019 Jun 14. doi: 10.1002/1878-0261.12532. [Epub ahead of print]

2.

Prebiotic effect of two grams of lactulose in healthy Japanese women: a randomised, double-blind, placebo-controlled crossover trial.

Sakai Y, Seki N, Hamano K, Ochi H, Abe F, Masuda K, Iino H.

Benef Microbes. 2019 May 27:1-12. doi: 10.3920/BM2018.0174. [Epub ahead of print]

PMID:
31131617
3.

Efficacy and safety of 4-weekly cabazitaxel for castration-resistant prostate cancer: a multi-institutional study.

Shiota M, Nakamura M, Yokomizo A, Tomoda T, Sakamoto N, Seki N, Hasegawa S, Yunoki T, Harano M, Kuroiwa K, Eto M.

Cancer Chemother Pharmacol. 2019 May 21. doi: 10.1007/s00280-019-03874-7. [Epub ahead of print]

PMID:
31115605
4.

A study of the prebiotic effect of lactulose at low dosages in healthy Japanese women.

Sakai Y, Seki N, Hamano H, Ochi H, Abe F, Shimizu F, Masuda K, Iino H.

Biosci Microbiota Food Health. 2019;38(2):69-72. doi: 10.12938/bmfh.18-013. Epub 2018 Dec 29.

5.

A Rare Case of Synchronous Cystic Duct Metastasis Arising from Renal Cell Carcinoma.

Ueda J, Makino H, Yokoyama T, Maruyama H, Hirakata A, Takata H, Seki N, Kikuchi Y, Yoshioka M, Irie T, Yoshida H.

J Nippon Med Sch. 2019 Apr 26. doi: 10.1272/jnms.JNMS.2018_86-405. [Epub ahead of print]

6.

Molecular Pathogenesis of Gene Regulation by the miR-150 Duplex: miR-150-3p Regulates TNS4 in Lung Adenocarcinoma.

Misono S, Seki N, Mizuno K, Yamada Y, Uchida A, Sanada H, Moriya S, Kikkawa N, Kumamoto T, Suetsugu T, Inoue H.

Cancers (Basel). 2019 Apr 30;11(5). pii: E601. doi: 10.3390/cancers11050601.

7.

Role of pre-miR-532 (miR-532-5p and miR-532-3p) in regulation of gene expression and molecular pathogenesis in renal cell carcinoma.

Yamada Y, Arai T, Kato M, Kojima S, Sakamoto S, Komiya A, Naya Y, Ichikawa T, Seki N.

Am J Clin Exp Urol. 2019 Feb 18;7(1):11-30. eCollection 2019.

8.

Gene Regulation by Antitumor miR-204-5p in Pancreatic Ductal Adenocarcinoma: The Clinical Significance of Direct RACGAP1 Regulation.

Khalid M, Idichi T, Seki N, Wada M, Yamada Y, Fukuhisa H, Toda H, Kita Y, Kawasaki Y, Tanoue K, Kurahara H, Mataki Y, Maemura K, Natsugoe S.

Cancers (Basel). 2019 Mar 7;11(3). pii: E327. doi: 10.3390/cancers11030327.

9.

Gene regulation by antitumor miR-130b-5p in pancreatic ductal adenocarcinoma: the clinical significance of oncogenic EPS8.

Fukuhisa H, Seki N, Idichi T, Kurahara H, Yamada Y, Toda H, Kita Y, Kawasaki Y, Tanoue K, Mataki Y, Maemura K, Natsugoe S.

J Hum Genet. 2019 Jun;64(6):521-534. doi: 10.1038/s10038-019-0584-6. Epub 2019 Mar 11.

PMID:
30858505
10.

Micro-ribonucleic acid expression signature of metastatic castration-resistant prostate cancer: Regulation of NCAPH by antitumor miR-199a/b-3p.

Arai T, Kojima S, Yamada Y, Sugawara S, Kato M, Yamazaki K, Naya Y, Ichikawa T, Seki N.

Int J Urol. 2019 Apr;26(4):506-520. doi: 10.1111/iju.13911. Epub 2019 Feb 28.

PMID:
30818424
11.

Efficacy and safety of cabazitaxel for castration-resistant prostate cancer in patients with > 10 cycles of docetaxel chemotherapy: a multi-institutional study.

Shiota M, Nakamura M, Yokomizo A, Tomoda T, Sakamoto N, Seki N, Hasegawa S, Yunoki T, Harano M, Kuroiwa K, Eto M.

Med Oncol. 2019 Feb 28;36(4):32. doi: 10.1007/s12032-019-1257-1.

PMID:
30815799
12.

Regulation of KIF2A by Antitumor miR-451a Inhibits Cancer Cell Aggressiveness Features in Lung Squamous Cell Carcinoma.

Uchida A, Seki N, Mizuno K, Yamada Y, Misono S, Sanada H, Kikkawa N, Kumamoto T, Suetsugu T, Inoue H.

Cancers (Basel). 2019 Feb 22;11(2). pii: E258. doi: 10.3390/cancers11020258.

13.

Promising Combination Therapy with Bevacizumab and Erlotinib in an EGFR-Mutated NSCLC Patient with MET Amplification Who Showed Intrinsic Resistance to Initial EGFR-TKI Therapy.

Seki N, Natsume M, Ochiai R, Haruyama T, Ishihara M, Fukasawa Y, Sakamoto T, Tanzawa S, Usui R, Honda T, Ota S, Ichikawa Y, Watanabe K.

Case Rep Oncol. 2019 Jan 21;12(1):91-97. doi: 10.1159/000493088. eCollection 2019 Jan-Apr.

14.

Need for Flexible Adjustment of the Treatment Schedule for Aprepitant Administration against Erlotinib-Induced Refractory Pruritus and Skin Rush.

Seki N, Ochiai R, Haruyama T, Ishihara M, Natsume M, Fukasawa Y, Sakamoto T, Tanzawa S, Usui R, Honda T, Ota S, Ichikawa Y, Watanabe K.

Case Rep Oncol. 2019 Jan 21;12(1):84-90. doi: 10.1159/000493256. eCollection 2019 Jan-Apr.

15.

Significance of Earlier Initiation of Chemotherapy for Lung Cancer Complicated with Primary or Secondary Nephrotic Syndrome following Its Appropriate Differential Diagnosis.

Ota S, Fujigaki Y, Tamura Y, Kojima K, Ochiai R, Haruyama T, Ishihara M, Natsume M, Fukasawa Y, Sakamoto T, Tanzawa S, Usui R, Honda T, Ichikawa Y, Watanabe K, Seki N.

Case Rep Oncol. 2019 Jan 11;12(1):53-58. doi: 10.1159/000493851. eCollection 2019 Jan-Apr.

16.

Successful Treatment with Taxane-Based Chemotherapy in Advanced Sebaceous Carcinoma: A Case Report and Literature Review.

Ota S, Sakamoto T, Ochiai R, Haruyama T, Ishihara M, Natsume M, Fukasawa Y, Tanzawa S, Usui R, Honda T, Ichikawa Y, Watanabe K, Sasajima Y, Mizota A, Seki N.

Case Rep Oncol. 2019 Jan 11;12(1):47-52. doi: 10.1159/000493850. eCollection 2019 Jan-Apr.

17.

[Development of a New Resilience Scale for Parents of Children with Profound Intellectual and Multiple Disabilities].

Tanaka M, Hisata M, Miyasaka M, Kurata K, Takizawa K, Nishikata M, Tohyama J, Seki N.

Nihon Eiseigaku Zasshi. 2019;74(0). doi: 10.1265/jjh.18025. Japanese.

18.

Discovery of Second Generation RORγ Inhibitors Composed of an Azole Scaffold.

Kotoku M, Maeba T, Fujioka S, Yokota M, Seki N, Ito K, Suwa Y, Ikenogami T, Hirata K, Hase Y, Katsuda Y, Miyagawa N, Arita K, Asahina K, Noguchi M, Nomura A, Doi S, Adachi T, Crowe P, Tao H, Thacher S, Hashimoto H, Suzuki T, Shiozaki M.

J Med Chem. 2019 Mar 14;62(5):2837-2842. doi: 10.1021/acs.jmedchem.8b01567. Epub 2019 Mar 1.

PMID:
30776227
19.

Benefits of a Nationwide Palliative Care Education Program on Lung Cancer Physicians.

Inoue A, Yamaguchi T, Tanaka K, Sakashita A, Aoe K, Seki N, Hagiwara K.

Intern Med. 2019 May 15;58(10):1399-1403. doi: 10.2169/internalmedicine.0872-18. Epub 2019 Feb 1.

20.

Effect of preoperative pregabalin in video-assisted thoracoscopic surgery.

Matsutani N, Seki N.

J Thorac Dis. 2018 Nov;10(Suppl 33):S4028-S4030. doi: 10.21037/jtd.2018.09.82. No abstract available.

21.

Economic analysis of palonosetron versus granisetron in the standard triplet regimen for preventing chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy in Japan (TRIPLE phase III trial).

Shimizu H, Suzuki K, Uchikura T, Tsuji D, Yamanaka T, Hashimoto H, Goto K, Matsui R, Seki N, Shimada T, Ikeda S, Ikegami N, Hama T, Yamamoto N, Sasaki T.

J Pharm Health Care Sci. 2018 Dec 10;4:31. doi: 10.1186/s40780-018-0128-9. eCollection 2018.

22.

Long-term safety and efficacy of antimuscarinic add-on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A multicenter, randomized study in Japan (MILAI II study).

Yamaguchi O, Kakizaki H, Homma Y, Igawa Y, Takeda M, Nishizawa O, Gotoh M, Yoshida M, Yokoyama O, Seki N, Okitsu A, Hamada T, Kobayashi A, Kuroishi K.

Int J Urol. 2019 Mar;26(3):342-352. doi: 10.1111/iju.13868. Epub 2018 Dec 13.

PMID:
30548692
23.

Prospective exosome-focused translational research for afatinib study of non-small cell lung cancer patients expressing EGFR (EXTRA study).

Okuma Y, Morikawa K, Tanaka H, Yokoyama T, Itani H, Horiuchi K, Nakagawa H, Takahashi N, Bessho A, Soejima K, Kishi K, Togashi A, Kanai Y, Ueda K, Horimoto K, Matsutani N, Seki N.

Thorac Cancer. 2019 Feb;10(2):395-400. doi: 10.1111/1759-7714.12923. Epub 2018 Dec 8.

24.

Molecular pathogenesis of esophageal squamous cell carcinoma: Identification of the antitumor effects of miR‑145‑3p on gene regulation.

Shimonosono M, Idichi T, Seki N, Yamada Y, Arai T, Arigami T, Sasaki K, Omoto I, Uchikado Y, Kita Y, Kurahara H, Maemura K, Natsugoe S.

Int J Oncol. 2019 Feb;54(2):673-688. doi: 10.3892/ijo.2018.4657. Epub 2018 Dec 6.

PMID:
30535463
25.

Yeast Mpo1 Is a Novel Dioxygenase That Catalyzes the α-Oxidation of a 2-Hydroxy Fatty Acid in an Fe2+-Dependent Manner.

Seki N, Mori K, Kitamura T, Miyamoto M, Kihara A.

Mol Cell Biol. 2019 Feb 15;39(5). pii: e00428-18. doi: 10.1128/MCB.00428-18. Print 2019 Mar 1.

PMID:
30530523
26.

Pirin: a potential novel therapeutic target for castration-resistant prostate cancer regulated by miR-455-5p.

Arai T, Kojima S, Yamada Y, Sugawara S, Kato M, Yamazaki K, Naya Y, Ichikawa T, Seki N.

Mol Oncol. 2019 Feb;13(2):322-337. doi: 10.1002/1878-0261.12405. Epub 2018 Dec 21.

27.

Relationship Between Sarcopenia and Both Physical Activity and Lifestyle in Patients With Chronic Liver Disease.

Ohashi K, Ishikawa T, Hoshi A, Suzuki M, Mitobe Y, Yamada E, Abeywickrama HM, Seki N, Koyama C, Aoki H, Koyama Y.

J Clin Med Res. 2018 Dec;10(12):920-927. doi: 10.14740/jocmr3640. Epub 2018 Oct 30.

28.

aCGH Analysis of Predictive Biomarkers for Response to Bevacizumab plus Oxaliplatin- or Irinotecan-Based Chemotherapy in Patients with Metastatic Colorectal Cancer.

Fujita Y, Taguri M, Yamazaki K, Tsurutani J, Sakai K, Tsushima T, Nagase M, Tamagawa H, Ueda S, Tamura T, Tsuji Y, Murata K, Taira K, Denda T, Moriwaki T, Funai S, Nakajima TE, Muro K, Tsuji A, Yoshida M, Suyama K, Kurimoto T, Sugimoto N, Baba E, Seki N, Sato M, Shimura T, Boku N, Hyodo I, Yamanaka T, Nishio K.

Oncologist. 2019 Mar;24(3):327-337. doi: 10.1634/theoncologist.2018-0119. Epub 2018 Nov 13.

PMID:
30425180
29.

Involvement of dual-strand of the miR-144 duplex and their targets in the pathogenesis of lung squamous cell carcinoma.

Uchida A, Seki N, Mizuno K, Misono S, Yamada Y, Kikkawa N, Sanada H, Kumamoto T, Suetsugu T, Inoue H.

Cancer Sci. 2019 Jan;110(1):420-432. doi: 10.1111/cas.13853. Epub 2018 Dec 6.

30.
31.

Molecular pathogenesis of triple-negative breast cancer based on microRNA expression signatures: antitumor miR-204-5p targets AP1S3.

Toda H, Kurozumi S, Kijima Y, Idichi T, Shinden Y, Yamada Y, Arai T, Maemura K, Fujii T, Horiguchi J, Natsugoe S, Seki N.

J Hum Genet. 2018 Dec;63(12):1197-1210. doi: 10.1038/s10038-018-0510-3. Epub 2018 Sep 18.

PMID:
30228364
32.

Molecular pathogenesis of renal cell carcinoma: Impact of the anti-tumor miR-29 family on gene regulation.

Yamada Y, Sugawara S, Arai T, Kojima S, Kato M, Okato A, Yamazaki K, Naya Y, Ichikawa T, Seki N.

Int J Urol. 2018 Nov;25(11):953-965. doi: 10.1111/iju.13783. Epub 2018 Aug 28.

PMID:
30153702
33.

Risk factors associated with chemotherapy-induced nausea and vomiting in the triplet antiemetic regimen including palonosetron or granisetron for cisplatin-based chemotherapy: analysis of a randomized, double-blind controlled trial.

Tsuji D, Suzuki K, Kawasaki Y, Goto K, Matsui R, Seki N, Hashimoto H, Hama T, Yamanaka T, Yamamoto N, Itoh K.

Support Care Cancer. 2019 Mar;27(3):1139-1147. doi: 10.1007/s00520-018-4403-y. Epub 2018 Aug 10.

PMID:
30094732
34.

Dual strands of the miR-145 duplex (miR-145-5p and miR-145-3p) regulate oncogenes in lung adenocarcinoma pathogenesis.

Misono S, Seki N, Mizuno K, Yamada Y, Uchida A, Arai T, Kumamoto T, Sanada H, Suetsugu T, Inoue H.

J Hum Genet. 2018 Oct;63(10):1015-1028. doi: 10.1038/s10038-018-0497-9. Epub 2018 Aug 6.

PMID:
30082847
35.

Postoperative empyema following lung cancer surgery.

Matsutani N, Yoshiya K, Chida M, Sakaguchi H, Kikkawa T, Fukuda H, Takahashi N, Sawabata N, Horio H, Seki N, Kawamura M.

Oncotarget. 2018 Jul 3;9(51):29810-29819. doi: 10.18632/oncotarget.25629. eCollection 2018 Jul 3.

36.

Reduction of Kiss1 expression in the anteroventral periventricular nucleus is associated with atrazine-induced attenuation of the luteinizing hormone surge in female rats.

Kimura M, Ishii MN, Seki N, Sakai Y, Yamashita T, Awatsuji H, Kanda K, Matsumoto K, Matsui H.

Biol Reprod. 2019 Jan 1;100(1):41-48. doi: 10.1093/biolre/ioy159.

PMID:
30010721
37.

Involvement of anti-tumor miR-124-3p and its targets in the pathogenesis of pancreatic ductal adenocarcinoma: direct regulation of ITGA3 and ITGB1 by miR-124-3p.

Idichi T, Seki N, Kurahara H, Fukuhisa H, Toda H, Shimonosono M, Yamada Y, Arai T, Kita Y, Kijima Y, Mataki Y, Maemura K, Natsugoe S.

Oncotarget. 2018 Jun 22;9(48):28849-28865. doi: 10.18632/oncotarget.25599. eCollection 2018 Jun 22.

38.

Regulation of antitumor miR-144-5p targets oncogenes: Direct regulation of syndecan-3 and its clinical significance.

Yamada Y, Arai T, Kojima S, Sugawara S, Kato M, Okato A, Yamazaki K, Naya Y, Ichikawa T, Seki N.

Cancer Sci. 2018 Sep;109(9):2919-2936. doi: 10.1111/cas.13722. Epub 2018 Jul 28.

39.

Anti-tumor roles of both strands of the miR-455 duplex: their targets SKA1 and SKA3 are involved in the pathogenesis of renal cell carcinoma.

Yamada Y, Arai T, Kojima S, Sugawara S, Kato M, Okato A, Yamazaki K, Naya Y, Ichikawa T, Seki N.

Oncotarget. 2018 Jun 1;9(42):26638-26658. doi: 10.18632/oncotarget.25410. eCollection 2018 Jun 1.

40.

Adenosquamous Carcinoma in the Midline Dorsum of the Tongue: A Rare Case Report.

Kikuta S, Todoroki K, Seki N, Kusukawa J.

J Oral Maxillofac Surg. 2018 Oct;76(10):2131-2135. doi: 10.1016/j.joms.2018.04.026. Epub 2018 May 1.

PMID:
29806990
41.

Relationship Between the Brain Natriuretic Peptide (BNP) Level and Prognosis of Diabetic Nephropathy with Microalbuminuria: A 7-Year Follow-Up Study.

Seki N, Matsumoto T, Fukazawa M.

Horm Metab Res. 2018 May;50(5):389-396. doi: 10.1055/a-0603-3792. Epub 2018 May 3.

PMID:
29723897
42.

Stress predictors in two Asian dental schools with an integrated curriculum and traditional curriculum.

Nguyen TTT, Seki N, Morio I.

Eur J Dent Educ. 2018 Aug;22(3):e594-e601. doi: 10.1111/eje.12358. Epub 2018 May 1.

PMID:
29717531
43.

Enhancement of motor-imagery ability via combined action observation and motor-imagery training with proprioceptive neurofeedback.

Ono Y, Wada K, Kurata M, Seki N.

Neuropsychologia. 2018 Jun;114:134-142. doi: 10.1016/j.neuropsychologia.2018.04.016. Epub 2018 Apr 23.

PMID:
29698736
44.

Molecular pathogenesis of pancreatic ductal adenocarcinoma: Impact of passenger strand of pre-miR-148a on gene regulation.

Idichi T, Seki N, Kurahara H, Fukuhisa H, Toda H, Shimonosono M, Okato A, Arai T, Kita Y, Mataki Y, Kijima Y, Maemura K, Natsugoe S.

Cancer Sci. 2018 Jun;109(6):2013-2026. doi: 10.1111/cas.13610. Epub 2018 May 22.

45.

Regulation of NCAPG by miR-99a-3p (passenger strand) inhibits cancer cell aggressiveness and is involved in CRPC.

Arai T, Okato A, Yamada Y, Sugawara S, Kurozumi A, Kojima S, Yamazaki K, Naya Y, Ichikawa T, Seki N.

Cancer Med. 2018 May;7(5):1988-2002. doi: 10.1002/cam4.1455. Epub 2018 Apr 2.

46.

Factors Influencing Cancer Patients' Choice of End-of-Life Care Place.

Natsume M, Watanabe K, Matsumoto S, Naruge D, Hayashi K, Furuse J, Kawamura M, Jinno H, Sano K, Fukushima R, Osawa G, Aruga E, Hashiguchi Y, Tanaka A, Takikawa H, Seki N.

J Palliat Med. 2018 Jun;21(6):751-765. doi: 10.1089/jpm.2017.0481. Epub 2018 Mar 22.

PMID:
29565216
47.

Dual strands of the miR-223 duplex (miR-223-5p and miR-223-3p) inhibit cancer cell aggressiveness: targeted genes are involved in bladder cancer pathogenesis.

Sugawara S, Yamada Y, Arai T, Okato A, Idichi T, Kato M, Koshizuka K, Ichikawa T, Seki N.

J Hum Genet. 2018 May;63(5):657-668. doi: 10.1038/s10038-018-0437-8. Epub 2018 Mar 14.

PMID:
29540855
48.

Molecular pathogenesis of interstitial cystitis based on microRNA expression signature: miR-320 family-regulated molecular pathways and targets.

Arai T, Fuse M, Goto Y, Kaga K, Kurozumi A, Yamada Y, Sugawara S, Okato A, Ichikawa T, Yamanishi T, Seki N.

J Hum Genet. 2018 May;63(5):543-554. doi: 10.1038/s10038-018-0419-x. Epub 2018 Mar 12.

PMID:
29531336
49.

Urinary afamin levels are associated with the progression of diabetic nephropathy.

Kaburagi Y, Takahashi E, Kajio H, Yamashita S, Yamamoto-Honda R, Shiga T, Okumura A, Goto A, Fukazawa Y, Seki N, Tobe K, Matsumoto M, Noda M, Unoki-Kubota H.

Diabetes Res Clin Pract. 2019 Jan;147:37-46. doi: 10.1016/j.diabres.2018.02.034. Epub 2018 Mar 6.

PMID:
29522788
50.

A Patient with Advanced Gastric Cancer Who Achieved a Long-Term Prognosis by Early Diagnosis of Sister Mary Joseph's Nodule.

Ota S, Haruyama T, Ishihara M, Natsume M, Fukasawa Y, Sakamoto T, Tanzawa S, Usui R, Honda T, Ichikawa Y, Watanabe K, Sasajima Y, Seki N.

Case Rep Oncol. 2018 Jan 4;11(1):11-16. doi: 10.1159/000484976. eCollection 2018 Jan-Apr.

Supplemental Content

Support Center